Obesity drugs have quickly become one of the fastest-growing classes of medication in the pharmaceutical industry. Because of their effectiveness in both diabetes and weight loss, GLP-1 receptor agonist drug products, like semaglutide and tirzepatide, have experienced extraordinary demand, altering the global pharmaceutical industry as demand has far exceeded manufacturing capacity.
GLP-1 drugs have been a game changer in the treatment of obesity. When their full potential was realized, commercial pressure for obesity therapies put pressure on pharmaceutical supply chains, especially for the active pharmaceutical ingredients (APIs) available supply simply could not meet the needs of the patient population served by the innovators. Now, the next generation of obesity drugs are in development, such as retatrutide, a promising triple-hormone agonist currently in phase 3 trials. As these peptide-based drugs progress towards the market, the need for specialized manufacturing capacity will only increase.
Pharmaceutical companies marketing these drugs need reliable API supply yet lead times can be long. As consumption of obesity drugs grows, pharmaceutical companies will have to strengthen their API supply chains to support reliable manufacturing and continued market growth. The importance of supplier validation, diversification, and long-term partnerships increases with the limited number of qualified manufacturers.
Let’s explore some of the historical supply chain challenges associated with GLP-1 obesity drugs.
Key Takeaways
- Demand for GLP-1 obesity drugs (semaglutide, tirzepatide) has outpaced peptide API manufacturing capacity, creating supply shortages and long lead times.
- The number of GLP-1 API manufacturers jumped from just 2-3 to over 20 in a short span, making supplier oversight and validation far more difficult, also, prompting 30+ FDA warning letters to compounding pharmacies.
- Peptide APIs are inherently harder to manufacture than small-molecule drugs. Even a 2-3x scale-up can require full re-validation, and impurity risks (aggregates, truncated peptides) are much higher.
- Generic peptide manufacturing has historically concentrated in China, creating geographic supply risk, though manufacturing capacity is now expanding in India as well.
- Next-generation therapies like retatrutide (currently in phase 3 trials) will keep pressure on manufacturing capacity, making supplier diversification and long-term sourcing partnerships increasingly important.
Supply Chain Challenges for Obesity Drugs
Limited global peptide manufacturing capacity created bottlenecks in API sourcing and led to the drug products being listed in short supply by the FDA. Regulatory exemptions allowed compounding pharmacies to provide these products to patients. Within a short space of time the number of API manufacturers offering GLP-1 APIs to the market increased from two or three to over 20. This influx of API sources made it difficult for manufacturers to ensure that their raw material suppliers were meeting FDA requirements. In fact, the FDA issued more than 30 warning letters to compounding pharmacies and needed to clarify its policies for compounders.
At the same time, long lead times for peptide APIs complicated production planning and inventory management. The fast-growing pipeline of next-generation obesity and metabolic therapies increased pressure on peptide manufacturing infrastructure. For these reasons, pharmaceutical companies increasingly require strategic, long-term sourcing partnerships to ensure supply continuity.
A further complication is that, traditionally, generic peptides have been manufactured in China, creating a geographic concentration risk in the supply chain. Manufacturers anticipating the opportunities presented by the growing obesity drug market are not waiting for patents to expire before preparing capacity to meet increasing patient and consumer demand.
Supplier Variability Poses Risks for Quality and Validation
As the number of API suppliers expanded rapidly, sourcing complexity and supplier variability increased, requiring more rigorous supplier qualification and oversight. Pharmaceutical companies faced quality and regulatory compliance requirements that added complexity to supplier selection and ongoing supply chain management.
It is essential that APIs are sourced from manufacturers that meet all FDA and applicable regulatory quality requirements. Pharmaceutical drug product manufacturers need to work with distributors that have an intimate knowledge of their drug substance suppliers. Although manufacturing capacity has increased in recent years, companies should evaluate available spare capacity to ensure suppliers can meet future commercial demand following product approval.
Manufacturing challenges
Many GLP-1 therapies rely on complex peptide-based APIs that require specialized manufacturing, extensive purification, and strict quality controls, making them more complex to manufacture and source compared to traditional small-molecule APIs.
Peptides are generally 10–40 amino acids long and are significantly more complex to manufacture than traditional small molecules, requiring multiple processing steps. They are produced by amino acid coupling cycles, protection/deprotection reactions, purification, final cleavage, and isolation. While small molecules, once validated, can be easily scaled 10-fold, peptide scale-up of even two- or three-fold can require re-validation to ensure integrity of the final product and acceptable impurity profile. Yield losses can be significant because, although coupling efficiencies may reach 99.5%, the cumulative impact across 20–30 cycles can substantially reduce overall yield. And impurity profiles are far more sensitive for peptides than for small molecules, including sequence-related impurities, aggregates, oxidized forms, and truncated peptides.
Expanding Capacity to Meet Future Demand
As therapies such as retatrutide and other next-generation metabolic drugs progress through clinical development, we do not anticipate significant new supply challenges, as peptide manufacturers continue expanding production capacity to meet future demand. In addition, we are currently seeing an increase in Indian peptide manufacturers moving into the obesity drug space.
This expansion will increase overall manufacturing capacity and geographic diversification of raw material supply, helping strengthen pharmaceutical supply chains over the long term.
Contact us today to learn how we can extend and protect your supply of critical raw materials.
Frequently Asked Questions
1. Why have obesity drugs created supply chain challenges?
The rapid growth in demand for GLP-1 therapies such as semaglutide and tirzepatide quickly exceeded available manufacturing capacity for peptide APIs. This created supply shortages, longer lead times, and increased competition for qualified manufacturing resources.
2. Why are peptide APIs more difficult to manufacture than traditional APIs?
Peptide APIs require complex multi-step manufacturing processes, including repeated amino acid coupling, purification, and quality control activities. Small changes during production can affect yield, impurity profiles, and overall product quality, making scale-up more challenging than traditional small-molecule APIs.
3. What risks are associated with sourcing peptide APIs?
Key risks include limited manufacturing capacity, supplier variability, regulatory compliance concerns, and geographic concentration of production. Companies must carefully qualify suppliers and evaluate their ability to support long-term commercial demand.
4. How can pharmaceutical companies strengthen their obesity drug supply chains?
Companies can reduce supply risk by qualifying multiple suppliers, establishing long-term sourcing partnerships, evaluating manufacturing capacity early, and working with experienced distributors that maintain strong supplier oversight programs.
5. Will supply constraints continue as new obesity drugs enter the market?
While demand for obesity therapies is expected to remain strong, significant investments in peptide manufacturing capacity are underway globally. Expanded production capabilities and increased geographic diversification should help improve long-term supply chain resilience as next-generation therapies reach the market.